Anticoagulated ICH: documentation that holds up

When an anticoagulated patient bleeds into the brain, the clock and the chart both start at the door. Reversal can't wait for the ICU — the defensible record identifies the agent and last dose, documents the time to reversal and blood-pressure control, and shows neurosurgery was engaged.

01What's at stake

Outcome hinges on limiting early hematoma expansion — every milliliter matters. Anticoagulated ICH carries higher mortality than non-anticoagulated, and a landmark cohort found a survival benefit when the INR was reversed to <1.3 and systolic BP brought below 160 within four hours of arrival. That four-hour window belongs to the emergency clinician.

02First, identify the agent

• Screen for every anticoagulant — warfarin, dabigatran, apixaban, rivaroxaban, edoxaban, and antiplatelets — and document the last dose timing. → a normal INR does not exclude a DOAC
• Warfarin: INR quantifies it.
• Dabigatran: a normal thrombin time essentially excludes effect; aPTT is only qualitative.
• Factor Xa inhibitors: a chromogenic anti-Xa level is the best measure; routine PT/aPTT are insensitive.

03Workup

• Glucose, then immediate non-contrast head CT. Consider CTA — the "spot sign" predicts hematoma expansion.
• Labs: CBC, electrolytes, PT/INR, aPTT; agent-specific assays where available.
• Have a low threshold for CT in an anticoagulated patient with headache or altered mental status — including the elder mislabeled "just dementia."

04Reverse fast — by agent

• Warfarin → 4-factor PCC (e.g., ~50 units/kg) plus IV vitamin K 5–10 mg. PCC corrects the INR faster and in less volume than FFP (which is inferior and volume-risky).
• Dabigatran → idarucizumab 5 g IV; if unavailable, consider PCC and/or hemodialysis (small, dialyzable molecule).
• Factor Xa inhibitors → andexanet alfa, or 4-factor PCC if unavailable (not dialyzable).
• Antiplatelets → platelet transfusion benefit is uncertain (consider DDAVP); avoid routine transfusion outside specific scenarios.

05BP, neurosurgery, disposition

• Blood pressure — start in the ED; for SBP 150–220, lowering to ~140 is safe (labetalol, nicardipine, or clevidipine infusions — often a drip, not boluses).
• Neurosurgery — supratentorial evacuation is usually not beneficial, but a cerebellar hemorrhage that is deteriorating or causing hydrocephalus needs emergent decompression/EVD.
• No prophylactic antiepileptics; treat only clinical/electrographic seizures.
• Disposition — neuroscience ICU; transfer rapidly (air transport is fine) if unavailable, with direct physician-to-physician handoff. Avoid an ED DNR if possible.

06What to document

07Where charts fail

• Deferring BP control and reversal to the ICU instead of starting in the ED.
• Assuming a normal INR rules out anticoagulation in a DOAC patient.
• Choosing FFP over PCC for warfarin reversal, or omitting IV vitamin K.
• Missing the deteriorating cerebellar hemorrhage / hydrocephalus needing surgery.
• Not documenting the agent, last dose, and the times to CT and reversal.

08Sources

• Kreitzer N, Adeoye O. Intracerebral hemorrhage in anticoagulated patients: evidence-based emergency department management. Emergency Medicine Practice (EB Medicine). 2015;17(12).
• Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in anticoagulation-related ICH. JAMA. 2015;313(8):824-836.
• Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: AHA/ASA. Stroke. 2015;46(7):2032-2060.
• Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy (ACCP). Chest. 2012;141(2 Suppl):e152S-e184S.

Note: reversal agents have evolved (e.g., andexanet alfa availability) — apply current guidance and local protocol.

© 2026 Kim Trinh, MD. All rights reserved. Educational only — synthesized from EB Medicine and primary literature. Synthetic examples. Not medical advice — apply local protocol and judgment.